Results 61 to 70 of about 14,793 (172)
Non-integrase mechanisms for dolutegravir resistance
Background Antiretroviral inhibitors that target specific aspects of human immunodeficiency virus 1 (HIV-1) replication have made a huge impact on the management of the global AIDS pandemic and the health and well-being of people that live with HIV ...
Alan N. Engelman
doaj +1 more source
This study investigates the impact of switching to long‐acting (LA) injectable cabotegravir and rilpivirine (CAB/RPV‐LA) on immune‐activation and ‐senescence in people with HIV (PWH). Thirty‐seven PWH switching to CAB/RPV‐LA and nine continuing oral ART were analysed over 72 weeks. LA therapy led to significant reductions in activation T and senescence
Mariasilvia Guardiani +16 more
wiley +1 more source
Human immunodeficiency virus (HIV) allosteric integrase inhibitors (ALLINIs) offer a vital alternative to standard therapies by targeting noncatalytic sites. By inducing aberrant integrase multimerization, they disrupt viral maturation. This review explores their medicinal chemistry evolution, detailing structural insights, structure–activity ...
Francesco Saccoliti +10 more
wiley +1 more source
Integrase (IN) represents a clinically validated target for the development of antivirals against human immunodeficiency virus (HIV). In recent years our research group has been engaged in the stucture-function study of this enzyme and in the development
Alba Chimirri +6 more
doaj +1 more source
This study compares the humoral and cellular immunogenicity of Dose 3 of Ancestral SARS‐CoV‐2 vaccine in participants with HIV and/or following lung transplantation with healthy controls. We highlight differences along a spectrum of immunocompromise, and the value of SARS‐CoV‐2 vaccination, even in the absence of detectable neutralisation responses ...
David WJ Griffin +15 more
wiley +1 more source
With the widespread use of integrase inhibitors and the expanding use of long-acting cabotegravir in both pre-exposure prophylaxis and antiretroviral treatment, molecular surveillance on the transmission of integrase resistance has regained clinical ...
Kaja Mielczak +14 more
doaj +1 more source
Signature HIV-1 integrase mutations associated with clinical raltegravir resistance involve 1 of 3 primary genetic pathways, Y143C/R, Q148H/K/R and N155H, the latter 2 of which confer cross-resistance to elvitegravir. In accord with clinical findings, in
Felix DeAnda +6 more
doaj +1 more source
First report of computational protein-ligand docking to evaluate susceptibility to HIV integrase inhibitors in HIV-infected Iranian patients. [PDF]
Ghasabi F +6 more
europepmc +1 more source
Targeted Interventions in HAM/TSP: Emerging Therapies and Future Directions – A Narrative Review
ABSTRACT Background and Aim Human T‐Lymphotropic virus type 1 (HTLV‐1) infection can lead to HTLV‐1‐associated myelopathy/tropical spastic paraparesis (HAM/TSP), a debilitating chronic neurological disease characterized by progressive lower limb spasticity and autonomic dysfunction.
Meygol Mirzaei Rezaei +11 more
wiley +1 more source
Styrylquinoline derivatives are demonstrated to be HIV-1 integrase inhibitors. On the basis of our previous CoMFA analysis of a series of styrylquinoline derivatives, N-[(2-substituted-styryl)-5-chloro-8-hydroxyquinolin-7-yl]-benzenesulfonamide ...
Li-Ming Hu +5 more
doaj +1 more source

